ArticleCureus2026
Role of Topical Nitroglycerin in Prevention and Management of Post-mastectomy Skin Flap Necrosis: A Prospective Randomized Controlled Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMastectomy skin flap necrosis is a common postoperative complication following breast cancer surgery and is associated with delayed wound healing, increased morbidity, prolonged hospital stay, additional surgical procedures, and delayed initiation of adjuvant therapy. Impaired flap perfusion is considered the primary underlying mechanism. Topical nitroglycerin, through nitric oxide-mediated vasodilation, has been proposed as a simple and cost-effective method to improve flap vascularity and reduce ischemic complications. This study aimed to evaluate the efficacy and safety of topical nitroglycerin in preventing and reducing post-mastectomy skin flap necrosis. MATERIALS AND
methodsA prospective, randomized, assessor-blinded, controlled study was conducted on 60 patients undergoing modified radical mastectomy (MRM). Patients were randomly allocated into two groups of 30 each. The intervention group received topical 2% nitroglycerin ointment, while the control group received topical povidone-iodine ointment. The primary outcome was the incidence of skin flap necrosis. Secondary outcomes included wound healing time, delayed wound healing, surgical site infection, debridement requirement, hospital stay, severity of flap necrosis, and treatment-related adverse events.
resultsSkin flap necrosis occurred in two (6.7%) patients in the nitroglycerin group compared with 10 (33.3%) patients in the control group. Patients receiving nitroglycerin demonstrated significantly faster wound healing, lower rates of delayed wound healing, and reduced requirement for surgical debridement. Full-thickness flap necrosis occurred only in the control group, and the mean necrotic area was significantly smaller among patients treated with nitroglycerin. Although surgical site infection and hospital stay were lower in the nitroglycerin group, these differences were not statistically significant. Adverse events were mild and self-limiting, with no treatment discontinuations.
conclusionTopical nitroglycerin is a safe and effective adjunct for reducing post-mastectomy skin flap necrosis and improving wound healing outcomes. Its routine use may improve postoperative recovery and reduce flap-related complications following MRM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.